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Effectiveness the pharmaceutical care in diabetic patients*
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SUMMARY
Objective: To determine the effectiveness of pharmaceutical care to improve control of type-2 diabetes
mellitus.
Methods: We carried out pharmacotherapeutical intervention during 19 months on patients with type-2
diabetes mellitus who were affiliate members of the contributive regime of the General System for Healthcare and
Social Security in  Bogotá and Cartagena. Through an interview and evaluation of medical records, we obtained
information about antidiabetic medications used, doses, other medications, along with Hemoglobin A1c level,
arterial pressure, serum low-density lipoprotein cholesterol level, nephropathy screening, retinal screening, foot
exams in the last year and problems associated with medication use by means of the DADER method Negative
Outcomes Associated with Medication (NOM).
Results: The study had a sample of 143 patients (64 intervened and 79 controls) with female predominance
(67.1% and 53.1%, respectively), mean age of 63.9±11.2 years. The patients in both groups were taking an average
of 6.0±2.7 medications. Initial HbA1c mean was 7.7% and 7.8%, without improvement by the end of the study
(7.4% for those intervened and 7.8% for the control group). Hypertension (81.1%) and dyslipidemia (62.9%) were
the most important comorbidities. About 50.4% of NOM were of effectiveness, follows 31.3% of necessity. The
mean cost per patient in controls was 1.4 greater than for the intervened group.
Conclusions: Increased effectiveness of the antidiabetic therapy was not demonstrated in patients intervened
with pharmacotherapeutical monitoring, but we did obtain a reduction in healthcare costs.
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Efectividad del seguimiento farmacoterapéutico en diabéticos tipo 2
RESUMEN
Objetivo: Determinar la efectividad del seguimiento farmacoterapéutico para mejorar el control de los
pacientes diabéticos tipo 2.
Métodos: Se realizó intervención farmacoterapéutica durante 19 meses a pacientes con diabetes mellitus tipo
2, afiliados al régimen contributivo del Sistema General de Seguridad Social en Salud en  Bogotá y Cartagena.
Mediante entrevista y revisión de la historia clínica, se obtuvo información sobre medicamentos antidiabéticos
utilizados, dosis, comedicación, resultados en último año de HbA1c, tensión arterial, perfil lipídico, albuminuria,
examen oftalmológico, valoración de pies y los Resultados Negativos Asociados con la Medicación (RNM) y se
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siguió la metodología DADER.
Resultados: Participaron 143 pacientes, 64 interve-
nidos y 79 controles, con predominio de mujeres (67.1%
y 53.1%, respectivamente), promedio de edad 63.9±11.2
años. Los pacientes de ambos grupos tomaban en pro-
medio 6.0±2.7 medicamentos. La HbA1c inicial tuvo
un promedio de 7.7% y 7.8% y al finalizar el estudio los
valores fueron de 7.4% y 7.8%, respectivamente en
cada grupo. El 50.4% de los RNM fueron de efectivi-
dad, seguido de 31.3% de necesidad. En la visita inicial
y final la recomendación farmacéutica fue aceptada y el
problema de salud resuelto en 72 casos (42.9% de
RNM) y en 46 casos (38.3% de RNM), respectivamen-
te. El cociente medio del costo por paciente en el grupo
control fue 1.4 veces mayor que en el intervenido.
Discusión: No se demostró aumento en la efectivi-
dad de la terapia antidiabética en pacientes interveni-
dos con seguimiento farmacoterapéutico, pero se con-
siguió una reducción en costos de la atención sanitaria.
Palabras clave: Diabetes mellitus; Hemoglobina A
glucosilada; Agentes hipoglucémicos;
Servicios farmacéuticos; Colombia.
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Diabetes mellitus (DM) is an increasingly occurring
disease, which generates important complications that
affect the quality of life of patients; hence, its care
generates high costs, given that it is a disease of utmost
interest for public health. DM affects 130-million
individuals around the world, 35-million are in America,
and nearly 19-million are in Latin America and the
Caribbean. It is calculated that by 2025 there will be
300-million diabetics in the world and 40-million of
these will live in our continent1-3. Diabetic patients do
not adequately adhere to pharmacological or nutritional
treatment, or to the recommended physical activity,
which are required to reach a suitable metabolic con-
trol, leading to the emergence of micro and macro-
vascular complications4. It has been estimated that 7%
of the Colombian population over 30 years of age
suffers from type-2 diabetes and 30% to 40% are
unaware of their condition1,4,5. Healthcare costs for
diabetic patients in Europe vary from 758€ annually in
1998, to 1476€ in 20026,7.
To reduce health complications and costs in
healthcare systems, strategies have been sought to
contribute to such aims and which directly involve the
pharmacist through a pharmaceutical care program,
developed by Hepler and Strand in 19908; its objective
is the optimization of the clinical results of the drug
therapy, improvement of patient quality of life,
contribution to the rational use of medications, and
detection, prevention, and solution to Negative
Outcomes Associated with Medication (NOM)9,10.
Pharmacotherapeutic Monitoring (PTM) is defined
as the professional practice in which the pharmacist
assumes responsibility for the needs of the patient
related to medications. It is a useful tool for contributing
to the adequate use of medications and guaranteeing
their safe, effective, and economic use. All this based
on good communication and cooperation between the
patient and health personnel9.
NOM, according to the Third Concensus of Grana-
da, are «health related problems or unwanted changes
in the patient’s state of health attributable to the use (or
lack of use) of medications. To measure NOM, we used
a clinical variable (symptom, signal, clinical event,
metabolic or physiologic measurement, death), which
does not fulfill the therapeutic objectives established
for the patient». NOM are classified into problems of
necessity, effectiveness, and safety; necessity NOM
include untreated health problems and the effects of
unnecessary medications, effectiveness NOM include
the quantified and non-quantified ineffectiveness, and
safety NOM include quantified and non-quantified
lack of safety9,10.
There is evidence in different countries around the
world that the lack of NOM detection and solution may
lead to additional costs in the healthcare system. A
study conducted in Spain in 2002 found that three out
of every four patients admitted to emergengy services
were because of an NOM11,12. There is also evidence in
that the results of pharmaceutical care may lead to
reduced utilization of healthcare services and to a lower
number of medications prescribed13.
In Colombia sufficient evaluations have not been
conducted on the results of pharmaceutical care. In
Medellín, a study carried out by Agudelo et al.14,
evaluated the economic impact of pharmaceutical
intervention in general ambulatory care, revealing a
savings in medications of US$931.16 and a savings in
laboratory tests of US$554 per patient per year.
Given that different studies have not been able to
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show the efficacy of pharmacotherapeutic monitoring
to better control the disease and even reduce healthcare
costs, we suggest the need for said intervention to aid in
optimizing the benefits in healthcare services for patients
with chronic treatments. A study was developed to
permit determining the efficacy of pharmacotherapeutic
monitoring and NOM identification to improve
metabolic control by reducing glycated hemoglobin
(HbA1c) in patients with type 2 diabetes mellitus in two
Colombian cities when comparing the usual care.
Additionally, we sought to determine the costs of
caring for these patients during the study period.
MATERIALS AND METHODS
An intervention study was carried out during 19
months, between May 2006 and January 2008, to
evaluate the effectiveness of pharmacotherapeutic
monitoring to reduce HbA1c in patients with type 2
diabetes mellitus. The study had the participation of
three pharmacist, two pharmacoepidemiologist
physicians, and the support of last semester phamacist
students from Universidad Nacional de Colombia in
Bogotá and Universidad de Cartagena in Cartagena.
The study was conveniently conducted in these cities
because there was trained personnel for said purpose.
Population and sample. From a universe of 3635
patients with type-2 diabetes, distributed in  Bogotá
(2960 patients) and Cartagena (675 patients), we selected
a a sample of 223 patients over 18 years of age (181
from  Bogotá and 42 from Cartagena), who were
receiving antidiabetic medication. All were affiliated
to two Healthcare Promotion Companies (EPS for its
acronynm in Spanish) in these cities. A possible 10%
loss of the number of patients in each group was
calculated.
The sample size was estimated as the comparison of
two proportions. The parameters were type-1 error at
0.05 and type-2 error at 0.2, with expected effectiveness
of 0.45 and relative risk of 1.5. Using the random
number table method, we assigned the groups in random
and stratified manner; 112 in the intervention group,
who had pharmacotherapeutic monitoring for 18 months;
and 111 in the control group, who were merely
interviewed at the beginning and at the end of the study.
Each of the patients had a replacement selected randomly
and with the same characteristics.
The study evaluated the following variables:
· Sociodemographic variables. Age, gender, weight,
marital status, type of healthcare affiliation (member
or beneficiary), socioeconomic level, and level of
education.
· Variables related to patient morbidity. Diagnosis,
time of evolution of the disease, antecedents of
complications (acute and chronic), antidiabetic
medication, via and frequency taken, co-morbidities,
medication for co-morbidities, time of evolution,
initial and final glycated hemoglobin (HbA1c), con-
trol paraclinical exams (fasting glucose, creatinine,
microalbuminuria, lipid profile), and body mass
index (BMI).
· Variables related to NOM. Number of NOM
detected, classification of NOM, causes of NOM,
and number of NOM solved (determined by how
physicians and pattients accept the pharma-
ceutical recommendations made by pharmaceutical
chemists).
· Variables related to costs. Costs of pharmacological
therapy; costs of healthcare in medical consultation,
specialist consultation, hospitalization (direct care
and paraclinical), and cost of hospitalization per
thousand inhabitants/day (CHD=(cost/365 x N°
inhabitants) x 1000).
· Dependent-response variables. Values of glycated
hemoglobin, number of visitis to a general phycisian;
number of visits to an endocrinologist; number of
visists to specialists because of diabetes-related
complications (cardiocerebrovascular, renal, ocu-
lar, peripheral vascular); number and cost of
medications prescribed per patient and number of
laboratory tests related with diabetes.
Inclusion criteria. Patients with type-2 diabetes
mellitus, affiliated to the contributive regime of two
EPS, who had continuity in antidiabetic treatment in the
three months prior, defined by attendance to medical
control and request for dispensing of normoglycemiant
medication; these patients were over 18 years of age
and accepted to participate in the study.
Exclusion criteria. Patients changing EPS during
the study; those whose physical or mental state did not
permit communicating with the interviewer; and patients
who did not remain in the city selected for the study
during the time it took to develop such.
Field work. The protocol was subjected to approval
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by the Bioethics Committee of the Faculty of Health
Sciences at Universidad Tecnológica de Pereira in
Colombia, as well as by the Ethics Committess of the
participating EPSs (committee minutes 30 March and
24 April 2006), in the category of «minimum-risk
research», according to Resolution N° 008430 of 1993
from the Colombian Ministry of Health, which
establishes scientific, technical, and administrative
norms for health research. All the patients were affiliated
to the General System of Health and Social Security
(SGSSS for its name in Spanish) and have no problems
obtaining the medications; all were registered in the
institutional program for diabetes control and, thus,
were receiving the care established by guidelines for
caring for this type of pathology.
The patients selected were notified by phone for
their participation in the study; they were then summoned
to be furnished the detais of their participation and to
sign an informed consent form once they accepted to
participate in the study. Patients in the intervention
group were subjected to glycated hemoglobin at the
start, at six months and at the end of the study;
additionally, an initial interview was conducted with
the pharmacotherapeutic record format, according to
the DADER methodology9. The status of the condition
was elaborated (including diagnosis, each of the
medications being taken, doses and dose intervals).
During the study, the patients were visited on at least
three instances, establishing the NOMs in each visit.
Patients in the control group were subjected to HbA1c
measurement at the beginning and end of the study;
they also had an initial interview with the pharmaco-
therapeutical record format, according to the DADER
methodology. The status of the condition was also
elaborated for this group and a final visit was conducted;
thereby, detecting the NOM.
After identifying NOM in each patient, the
pharmacist suggested for the patients in the intervention
group activities to solve the health problem associated
to medication use, socializing said activities with the
healthcare team through a written documment. Upon
changes in medication, a new condition status was
established, which also evaluated the acceptance or
non-acceptance of the physician’s pharmaceutical
recommendations.
Phone calls and visits were also made every four
months to inquire about hospitalizations, visits to the
general physician, specialist, and emergency services.
Physicians from EPSs were informed on the objectives
and benefits of the pharmaceutical monitoring study
and of the importance of their active participation in the
program to offer complete patient care.
Sources of information. Pharmacotherapeutic
records were the primary source of information and the
secondary sources were the clinical histories, the status
of the condition, records of medications dispensed by
quantities and costs, along with the data base from the
EPS services with the records of services rendered to
their users, appointments with their treating physicians,
authorizations for paraclinical exams requested by the
physicians, among others.
Analysis of information. The SPSS 15.0 for
Windows statistical package was used for data analysis.
Parametric and non-parametric hypotheses tests were
run for related samples, comparing the initial and final
glycated hemoglobin within the same groups. Because
the statistics for hypothesis tests were not significant,
we opted for a bivariate analysis for the quantitative
parameters via hazard ratios. Statistical significance
was established at p<0.05. A descriptive analysis was
performed of the cost variable for each of the EPSs and
in each of the groups. Additionally, we conducted an
analysis of the increasing cost-effectiveness ratios for
each EPS.
RESULTS
General findings. The study initially had 223
patients, 112 in the intervention group and 111 in the
control group, but during the course of the study 80
patients were lost from the sample because of different
causes, ending the study with 143 patients (64.1% of
the original total) (Figure 1). Of the patients finishing
the study, 143 were from  Bogotá  and 20 from Cartagena.
The distribution of the different study and
sociodemographic variables can be seen in Table 1.
Mean age was 63.9±11.2 years, ranging from 30 to 86
years of age. Upon comparing the initial average body
mass index (BMI) with that of the final visit no
statistically significant differences were found (p=0.09
and p=0.052, respectively); with a range between 18.5
and 40 kg/m2. Only 39 patients (27.3%) registered in
the clinical history results of creatinine, eight patients
(5.6%) revealed microalbuminuria, and only 25.9% of
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Figure 1. Flow chart of losses and analysis of the pharmacotherapeutical monitoring of
patients with type 2 diabetes mellitus
the patients registered a complete evaluation of the lipid
profile and merely 7.7% were evaluated for thyroid
stimulating hormone (TSH).
HbA1c findings and antidiabetic medication
consumption. When comparing initial and final HbA1c
values of the study, the average for the intervention
group was 7.4% (p=0.0556; IC 95%: 7.0%-7.7%); and
in the control group HbA1c was 7.8% (p=0.93; IC 95%:
7.3%-8.1%). Mean levels of initial basal glycemia were
at 146 mg/dl for the intervention group and 143 mg/dl
for the control group; while at the end of the study these
values were 124 mg/dl vs. 136 mg/dl, respectively.
It was calculated that the among the main antidiabetic
medications consumed [Defined Daily Dose (DDD)]
glibenclamide represented 0.57 DDD per 1000
inhabitants/day, insulin 0.002 DDD per 1000 inhabitants/
day, and metformin 4.61 DDD per 1000 inhabitants/
day. It was found that on the average, the patients were
receiving 1.17 of the DDD of glibenclamide, 1.61 of the
DDD of insulin, and 0.86 of the DDD of metformin.
Co-morbidities and co-medication. The most
prevalent co-morbidities were hypertension, dislipi-
demia, and hypothyroidism and the most frequent long-
term complications can be seen in Table 2. We were
able to identify in the patients in the study another 260
less prevalent health problems. We observed an avera-
ge of 6.4±2.8 additional pathologies per patient for the
intervention group and 6.0±2.4 for the control group,
during the first visit. The most frequently identified co-
medication corresponded to antihypertensive,
hypolipidemic, thryroid hormone, antiplatelet drugs,
among others.
Negative outcomes associated with medication.
During each of the interviews of the patients in the
intervention and control groups, we identified the NOM
and the possible causes. Table 2 shows the NOM
identified, with those relating to effectiveness being the
most frequent (50.4%), followed by the necessity NOMs
(31.3%). The greatest number of NOM was identified
for antidiabetic medications with 232 cases (103 for
metformin (44.4%), 72 for insulin (31%), and 57 for
glibenclamide (24.7%); followed by 109 cases of
antiplatelet drugs; then hypolipidemic drugs with 98
cases 78 for lovastatin (79.6%), 14 for gemfibrozil
(20.4%), and 93 cases for antihypertensive medications.
The most frequent NOM causes in these four
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pharmacological groups were thus: 126 (54.3%) of the
NOMs associated to use of antidiabetic drugs were
caused by inadequate dosage, guideline, or duration of
the treatment; 98 (89.9%) of the NOMs associated to
antiplatelet drugs were related to an insufficiently treated
health problem; 40 of the hypolipidemic NOM (40.8%)
were from the category belonging to insufficiently
treated health problem; and 22 (23.6%) of the NOM
associated to antihypertensive medications were caused
by inadequate dosage, guideline, or duration of
treatment. Causes of NOM identified in the study
patients can be seen in Table 3.
Solution of negative outcomes associated with
medication. During the initial and final visits for the
intervention group, the intervention was accepted and
the health problem was solved in 72 cases (42.9% of
NOM) and 46 cases (38.3% of NOM), respectively.
The intervention was accepted but the health problem
was not solved in 21 cases (12.5%) during the initial
visit and 16 cases (13.3%) during the final visit. The
intervention was not accepted but the health problem
was solved in 8 cases during the initial visit (4.8%) and
7 cases during the final visit (5.8%). The intervention
was not accepted and the health problem was not solved
during the first visit in 67 patients (39.9%) and during
the final visit in 51 patients (42.5%). No important
differences were found with the control group.
Costs. The descriptive analysis revealed the
following: Total medical costs were $170’867,819
Table 1
Sociodemographic and study variables of type-2
diabetic patients and of patients from the
intervention and control groups in the cities of
Bogotá and Cartagena, 2006-2008
    Variable                        Intervention     Control
Age 63.4 ± 11.7 64.2 ± 10.8
Gender
  Male 21 (32.8%) 37 (46.8%)
  Female 43 (67.2%) 42 (53.2%)
Study Variables
  Initial A1c Hemoglobin 7.7 ± 1.8 7.8 ± 2.0
  Final A1c Hemoglobin 7.4 ± 1.8 7.8 ± 1.7
  Initial body mass index 27.8 ± 5.5 26.9 ± 6.1
  Initial N° of medications 5.8 ± 2.4 6.4 ± 2.9
  Final N° of medications 6.7 ± 2.4 7.4 ± 3.2
  N° NOMs identified 2.6 ± 1.6 2.1 ± 1.4
Comorbidities
  Hypertension 76.6% 84.8%
  Dislipidemia 57.2% 67.1%
  Hypothyroidism 17.2% 17.7%
Long-term complications
  Ophthalmological 17.2% 10.1%
  Renals 12.5% 11.4%
  Neurological 14.1% 7.6%
Table 2
Distribution of NOMs identified during each visit in type-2 diabetic patients from the intervention
and control groups in the cities of Bogotá and Cartagena, 2006-2008
          NOM identified                                  Initial visit    Follow up             Final visit            Total NOMs      Relative
              Intervention   Control   intervention   Intervention   Control     identified    frequency (%)
Untreated health problems 46 45 30 20 22 163 23.4
Effects of unnecessary medications 16 19 8 2 10 55 7.9
Non-quantitative ineffectiveness 21 8 11 6 6 52 7.5
Quantitative ineffectiveness 47 67 56 62 67 299 42.9
Non-quantitative insecurity 33 25 11 17 18 104 14.9
Quantitative insecurity 5 7 5 3 4 24 3.4
Total 168 171 121 110 127 697 100.0
NOM/patient 2.6 2.2 1.9 1.7 1.6 4.9
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Colombian pesos (CP) for the 143 patients with whom
the study was completed, distributed by $62’489,389
CP (36.6% of the cost) for the 63 participants from the
intervention group and $108’378,430 CP (63.4% of the
cost) for the 79 cases from the control group. The cost
per thousand inhabitants per day (CID) was $228.7 CP
for glibenclamide, $2,793.6 CP for insulin, and $3,256.3
CP for metformin.
Two cases were eliminated to diminish bias due to
extreme values; the average direct cost per patient from
the intervened group was $976,397 CP and $1’371,879
CP for the control group, during the study. It was noted
that the mean ratio (average per patient) for the patients
in the control group was 1.4 times greater than in the
intervention group, suggesting that medical costs of
patients from the intervention group were lower.
Analysis per healthcare insurance carrier revealed that
the difference in the mean ratio of the direct cost was in
the range of 1.1 times to 2.5 times greater in patients
from the control group, in relation to the intervention
group; leading us to interpret that conducting
pharmaceutical intervention is a more effective option
in diminishing medical costs. It must be stated that the
pharmacotherapeutic monitoring was carried out by the
drug dispensing entity and not by the healthcare provider,
for this reason the cost was not charged to the direct
costs of patient healthcare.
DISCUSSION
Poor control of patients with type-2 diabetes mellitus
is a problem affecting all nations. In developed nations
as in developing nations, effectiveness of the therapy
measured by controlling HbA1c figures ranges between
31.0% and 49.8%16-19. It is worth mentioning that in the
study carried out, there was an important loss of patients
(35.8%); hence, the authors are aware of the difficulties
this generates in interpreting the results and the bias that
can be generated, with the loss of patients being greater
for the intervention group than in the control group
(46.9% vs. 28.9%, respectively).
As with other studies, women were more willing to
participate, which may be related to the greater
prevalence of diabetes in this gender; with a mean age
of 63 years and with overweight or obesity condi-
tions16,20. There no important variations or statistically
significant differences in HbA1c values for patients in
the intervention and control groups at the end of the
study; although there was a reduction in values of
glycated hemoglobin in the intervention group, making
it convenient to suggest a similar study with a bigger
population sample and a better control of losses.
Along with other studies, during the initial interview,
we found co-morbidities frequently associated to dia-
betes, such as hypertension (81.1%), dislipidemia
(62.9%)16,20. Renal, ophthalmic, neurological, and
vascular peripheral complications are very important in
patients with type-2 diabetes, which contrasts with that
found in the study, with scarce request for important
tests like measurement of microalbuminuria, serum
creatinine, lipid profile, and eye exam16.
The finding of a high percentage of ineffectiveness
NOM (50.4%) is related to the poor control of type-2
diabetes mellitus in patients; although this disease
Causes of NOM
Table 3
Causes of NOM in each group studied during the initial visit, the follow up visit, and the final visit of
patients with type-2 diabetes in the cities of Bogotá and Cartagena, 2006-2008
                                                                 Initial visit        Follow up            Final visit             Total   Simple
                                                        Intervention  Control   intervention   Intervention  Control             relative
        frequency
Inadequately treated health problem           66      52              50               36            24       228    32.7
Inadequate dosage, guideline, or duration 29 50 29 38 50 196 28.1
Possibility of adverse effects 31 23 10 13 14 91 13.1
Non-compliance 15 16 13 14 20 78 11.2
Others 27 30 19 9 19 104 14.9
Total 168 171 121 110 127 697 100
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needs multidisciplinary attention (adequate nutrition,
regular physical exercise, healthy habits, and pharma-
cological treatment), monitoring with HbA1c is a good
guide to make the pertinent adjustments to the
treatment16.
The high frequency of the necessity NOM (31.3%)
is probably associated to inadequate care of the patients,
because of defficiencies in evaluating the disease, the
co-morbidities, and the cardiovascular risk; particularly
because of the underutilization of acetylsalicylic acid
in secondary prevention in patients with high cardio-
vascular risk. Suggested interventions in pharmaco-
therapeutic monitoring, to correct this finding, may
greatly benefit patients, possibly diminishing morbidity
and mortality because of cardiocerebrovascular events
associated to the use of said antiplatelet drug10.
Inadequate dossage (28.1%) was also identified as
causing NOM, with daily defined dossages (DDD)
lower than those established by the World Health
Organization (WHO) for the different antidiabetic
medications, especially for metformin. The adverse
effects (13.1% identified for these medications) affect
adherence and may aggravate patient morbidity.
The economic analysis between conducting
interventions or keeping patients under habitual con-
trol, suggests to healthcare insurance carriers that
implementing pharmacotherapeutic monitoring
programs in patients with type-2 diabetes, may generate
savings in costs related to caring for these patients. On
the average, a patient from the intervention group
generated a cost of $395,482 CP less than a patient from
the control group during the 19-month study period.
This finding warrants conducting a more profound
study of the impact expected of pharmacotherapeutic
monitoring on the cost of healthcare. Costs per 1000
inhabitants/day for each of the antidiabetic medications
were lower than those reported by other studies carried
out in Europe21.
This study presented a series of difficulties worth
describing because they may be useful for those who
may implement pharmacotherapeutic monitoring, such
as: problems in obtaining a doctor’s office for the
interview between the pharmacist and the patients at the
locations where the patients are normally cared. The
need to schedule home visits requiring greater
investment of time when the patient’s health status does
not permit attending the healthcare facility. Very
frequently, the medical histories do not contain sufficient
and necessary information for the case analysis in
pharmacotherapeutical monitoring, given that many
patients are seen by hired specialists, who generate
reports different from those in the medical chart at the
EPS, and access to this information is difficult in spite
of multiple requests. Some treating physicians do not
follow the guidelines for treatment of diabetes mellitus
and do not make opportune requests for paraclinical
and medical exams necessary for the complete analysis
in pharmacotherapeutical monitoring. The researchers
could not guarantee that the written reports with the
intervention recommendations made by a pharmacist
reached the treating physician; thus, the suggested
intervention would or would not be accepted upon the
detection of an NOM. Many of these difficulties came
about because of the lack of support and commitment
with the study from personnel in the participating
healthcare insurance carriers.
The loss of 35.8% of the patients generated an
important difficulty in analyzing the results to determi-
ne the effectiveness of pharmacotherapeutic monitoring
of type-2 diabetic patients. The situations that could be
related to the loss of patients include: prolonged duration
of the study, change of EPS by several patients and
change of address without notification of the new
domicile, which made it difficult to locate the patient
for the monitoring.
This study did not reveal increased effectiveness in
treatment of patients with type-2 diabetes mellitus,
which also occurred in the study by Beney et al.13; but
a reduction was found in costs of medical care in the
intervention group; along with determining the most
important and most frequent NOM to suggest
interventions destined to improving them.
In the future, in case pharmacotherapeutic monitoring
is incorporated to daily care of diabetic patients,
commitment is needed from healthcare insurance
carriers (EPS) to make available the offices for the
interviews, facilitate easier access to clinical records
and paraclinical exams, updates of member addresses,
generation of settings for meetings and discussion with
treating physicians to socialize the NOM findings and
the pharmaceutical recommendations, implement
recommendations, and evaluate results. Finally, it must
be stated that the results are only applicable to
populations of diabetic patients with similar charac-
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teristics who are affiliated to the contributive healthcare
regime of Colombia’s General System of Health and
Social Security.
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